Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma

Journal of Immunology

Volumn 168, Issue 1, 2002, Pages 466-474

  Zhang, Q ^a   Raghunath, P N ^a   Xue, L ^a   Majewski, M ^a   Carpentieri, D F ^a   Odum, N ^a   Morris, S ^a   Skorski, T ^a   Wasik, M A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CHIMERIC KINASE; DNA; NUCLEOPLASMIN; PHOSPHATASE; PHOSPHATASE 3A; PHOSPHOTRANSFERASE; PROTEIN INHIBITOR; STAT3 PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA BINDING; FEMALE; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NULL CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T CELL LYMPHOMA; T LYMPHOCYTE;

EID: 0036134884     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.1.466     Document Type: Article

References (88)

1. Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: A distinct clinicopathologic entity
2. ALK-positive lymphoma: A single disease with a broad spectrum of morphology
3. ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum
4. The t(2;5) in humans
5. The pathologic and clinical spectrum of anaplastic large cell lymphoma and correlation with ALK gene dysregulation
6. A new subtype of large B -cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation
7. + lymphoma: Clinico-pathological findings and outcome
8. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma
9. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma
10. Absence of the t(2;5) in Hodgkin's disease
11. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction
12. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions
13. + anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease
14. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease: Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining
15. Molecular characterization of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma (ki-1) and Hodgkin's disease
16. Occurrence of the t(2;5)(p23;q35) in non-Hodgkin's lymphoma
17. + primary cutaneous lymphoproliferative disorders and Hodgkin's disease
18. Amplification of genomic DNA demonstrates the presence of the t(2;5)(p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis
19. Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALKI
20. The monoclonal antibody ALKI identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements
21. + lymphoproliferative disorders: Comparison with anaplastic large-cell lymphoma of nodal origin
22. Detection of the t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis
23. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system
24. CD30-positive large cell lymphomas ("Ki-1 lymphoma") are associated with a chromosomal translocation involving 5q35
25. The cryptic inv(2)(p23q35) defines a new molecular genetic subtype of ALK-positive anaplastic large-cell lymphoma
26. Complex variant translocation t(1;2) with TPM3-ALK fusion due to cryptic ALK gene rearrangement in anaplastic large-cell lymphoma
27. t(1;2)(q21;p23) and t(2;3)(p23; q21): Two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma
28. A new fusion gene TPM3-ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocalion
29. TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations
30. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK
31. A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma
32. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35)
33. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 Cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like)
34. Major nucleolar proteins shuttle between nucleus and cytoplasm
35. Characterization of the cDNA encoding human nucleophosmin and studies of its role in normal and abnormal growth
36. Interaction of nucleolar phosphoprotein B23 with nucleic acids
37. DNA cloning and amino acid sequence determination of a major constituent protein of mammalian nucleoli: Correspondence of the nucleoplasmin-related protein NO38 to mammalian protein B23
38. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma
39. Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3
40. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)
41. Characterization of the transforming activity of p80, a hyperphosphorylated protein in a Ki-1 lymphoma cell line with chromosomal translocation t(2;5)
42. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis
43. The activated anaplastic lymphoma kinase increases cellular proliferation and oncogene up-regulation in rat Ia fibroblasts
44. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice
45. Nucleolar localization of the nucleophosminanaplastic lymphoma kinase is not required for malignant transformation
46. The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma
47. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway
48. JAKS and STATS: Biological implications
49. The STAT family of proteins in cytokine signaling
50. Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3
51. Specific inhibition of STAT3 signal transduction by PIAS3
52. The (2;5) (p23;g35) translocation in cell lines derived from malignant lymphomas: Absence of t(2;5) in Hodgkin-analogous cell lines
53. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone
54. Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome
55. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact src homology (SH3) and SH2 domains of BCR/ABL and is required for leukemogenesis
56. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter
57. Immunosuppressive macrolide SDZ RAD inhibits growth of human EBV-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders (PTLDs)
58. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-1
59. Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) Tax protein or virus-transformed cells
60. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: Tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines
61. Differences in phosphorylation of the IL-2R associated Jak/STAT proteins between HTLV-I(+), IL-2-independent and IL-2-dependent cell lines and uncultured leukemic cells from patients with adult T-cell lymphoma/leukemia (ATLL)
62. Interleukin 2 and 15 activate Stat3α in human T lymphocytes
63. Inhibition of Stat1-mediated gene activation by PIAS1
64. Protein phosphorylation and dephosphorylation in physiologic and oncologic processes
65. Leukocyte protein kinases: Potential targets for drug discovery
66. The hallmarks of cancer
67. Tyrosine kinase inhibition: An approach to drug development
68. Mechanism-based target identification and drug discovery in cancer research
69. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
70. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
71. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
72. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
73. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia
74. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
75. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
76. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-γ to mediate its mitogenicity
77. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis
78. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidytinositol 3-kinase/Akt antiapoptotic signaling pathway
79. The role of STAT in proliferation, differentiation, and apoptosis
80. STAT signaling in the pathogenesis and treatment of cancer
81. Stat3 activation by Src induces specific gene regulation and is required for cell transformation
82. Stat3 activation is required for cellular transformation by v-src
83. Stat3 as an oncogene
84. Stat3-mediated transformation of NIH-3T3 cells by the constitutively active Q205L Go protein
85. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
86. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo
87. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells
88. The NPM/ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells